Cannabis and mental health: separating fact from fiction in the context of cannabinoid and individual profiles
October 10th is World Mental Health Day. Here is a look back at the latest studies to date.
The question of the impact of cannabis on psychological balance remains one of the most polarizing topics in modern psychiatry. On one hand, a large segment of users finds respite from anxiety disorders or low moods (up to 67% of declared beneficial effects on mental health). On the other, medical literature warns of the risks of relapse, addiction, and the aggravation of certain disorders.
For the authors of the study The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors, Kelly A. Sagar and Staci A. Gruber (2025), this apparent contradiction is explained mainly by a fundamental error: considering "cannabis" as a single entity. In reality, the effect on the brain depends closely on the molecules consumed, usage habits, and the specific physiology of each individual.
1. The molecular duality: the clash between THC and CBD
Historically, almost all research has focused on recreational cannabis, whose primary objective is intoxication.
- Δ9-THC (delta-9-tetrahydrocannabinol): This is the plant's main psychoactive agent. Repeated, high-dose exposure to THC is generally correlated with negative clinical outcomes (psychotic disorders, increased anxiety, severity of addiction).
- CBD (cannabidiol): Devoid of any euphoric or intoxicating effect, this cannabinoid arouses immense hope in psychiatry. Clinical trials demonstrate its anxiolytic, antipsychotic, and mood-regulating properties. For example, some studies compare its efficacy to that of traditional antipsychotics, but with a much better tolerance profile and significantly fewer adverse side effects (absence of weight gain or endocrine dysfunction).
Understand in detail the differences between THC and CBD.
2. Decoding the impacts according to the targeted pathologies
- Psychotic disorders: Cannabis does not trigger schizophrenia on its own, but it acts as a precipitating risk factor in vulnerable subjects. THC-rich strains aggravate relapses and prolong hospitalizations. In contrast, the administration of CBD shows real potential for soothing psychotic symptoms.
- Anxiety and stress: While THC presents biphasic effects (relaxant at very low doses, anxiogenic at high doses), CBD remains constant: it never increases anxiety and significantly reduces the symptoms of generalized anxiety disorder, social phobia, or OCD.
- Mood and depression: Non-medical (recreational) cannabis use is often associated with heavier depressive episodes and suicidal ideation. Conversely, the use of medical cannabis or CBD-rich formulations highlights lasting improvements in mood and cognitive performance.
- Post-Traumatic Stress Disorder (PTSD): Faced with the limitations of conventional treatments (antidepressants with high failure rates), many patients self-medicate. While relief is sometimes sought, the uncontrolled use of products highly concentrated in THC can exacerbate hyper-vigilance and worsen the pathology, hence the importance of targeting safe therapeutic ratios.
3. Key factors that modulate the equation
To fully understand how an organism reacts to cannabis, three major variables must be taken into account:
- Consumption habits and products: The choice of variety (THC vs. CBD dominance), frequency of use, and route of administration play a determining role. Inhaling ultra-potent concentrates (dabs) multiplies psychiatric risks, while oral administration exposes the body to hepatic metabolism (CYP450), increasing the risk of drug interactions with psychotropics. "Full-spectrum" products, combining minor cannabinoids, terpenes, and flavonoids, also benefit from an "entourage effect" that maximizes efficacy at lower doses, such as our selection of CBD resins.
- Age and cerebral maturity: The endocannabinoid system evolves over the course of a lifetime. In adolescents and young adults, whose brains are still in full development (and the density of CB1 receptors is at its maximum), THC disrupts the neurodevelopmental trajectory, promoting future cognitive or anxiety disorders. Conversely, in older adults, low doses of cannabinoids can prove beneficial for sleep, mood, and brain plasticity, as the system's overall activity naturally tends to decline with age.
- Sex and genetics: Sexual dimorphisms exist (women metabolize cannabinoids differently and sometimes show greater sensitivity to the acute anxiogenic effects of THC). Furthermore, individuals with direct family histories of psychotic disorders show increased vulnerability to THC.
In summary: towards precision medicine
The study by Sagar & Gruber invites caregivers and patients to look beyond preconceived ideas. Cannabis is neither an absolute danger nor a universal miracle cure. The future lies in a personalized and modulated approach, favoring non-intoxicating, CBD-rich profiles while taking into account each patient's age, genetic predispositions, and biological profile.
